JPH03195489A - Production of spherical formed product of immobilized biocatalyst - Google Patents
Production of spherical formed product of immobilized biocatalystInfo
- Publication number
- JPH03195489A JPH03195489A JP33381189A JP33381189A JPH03195489A JP H03195489 A JPH03195489 A JP H03195489A JP 33381189 A JP33381189 A JP 33381189A JP 33381189 A JP33381189 A JP 33381189A JP H03195489 A JPH03195489 A JP H03195489A
- Authority
- JP
- Japan
- Prior art keywords
- aqueous solution
- pva
- spherical
- gel
- polyvinyl alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 21
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 21
- 239000011942 biocatalyst Substances 0.000 title claims abstract description 17
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- 239000004372 Polyvinyl alcohol Substances 0.000 claims abstract description 80
- 229920002451 polyvinyl alcohol Polymers 0.000 claims abstract description 80
- 239000007864 aqueous solution Substances 0.000 claims abstract description 53
- 150000001768 cations Chemical class 0.000 claims abstract description 19
- 150000001875 compounds Chemical class 0.000 claims abstract description 16
- 238000006116 polymerization reaction Methods 0.000 claims abstract description 10
- 150000004676 glycans Chemical class 0.000 claims abstract description 7
- 239000007788 liquid Substances 0.000 claims abstract description 7
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 7
- 239000005017 polysaccharide Substances 0.000 claims abstract description 7
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000000661 sodium alginate Substances 0.000 claims abstract description 6
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 6
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 6
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims abstract description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical group [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 4
- 239000001110 calcium chloride Substances 0.000 claims abstract description 4
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 6
- 230000002195 synergetic effect Effects 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 25
- 239000011259 mixed solution Substances 0.000 abstract description 3
- 235000011148 calcium chloride Nutrition 0.000 abstract description 2
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 72
- 239000000499 gel Substances 0.000 description 46
- 238000000034 method Methods 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 9
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 5
- 229940072056 alginate Drugs 0.000 description 5
- 235000010443 alginic acid Nutrition 0.000 description 5
- 229920000615 alginic acid Polymers 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 238000007127 saponification reaction Methods 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- -1 aluminum ions Chemical class 0.000 description 3
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical class OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 241000228212 Aspergillus Species 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000010802 sludge Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- WJQZZLQMLJPKQH-UHFFFAOYSA-N 2,4-dichloro-6-methylphenol Chemical compound CC1=CC(Cl)=CC(Cl)=C1O WJQZZLQMLJPKQH-UHFFFAOYSA-N 0.000 description 1
- ULGJWNIHLSLQPZ-UHFFFAOYSA-N 7-[(6,8-dichloro-1,2,3,4-tetrahydroacridin-9-yl)amino]-n-[2-(1h-indol-3-yl)ethyl]heptanamide Chemical compound C1CCCC2=NC3=CC(Cl)=CC(Cl)=C3C(NCCCCCCC(=O)NCCC=3C4=CC=CC=C4NC=3)=C21 ULGJWNIHLSLQPZ-UHFFFAOYSA-N 0.000 description 1
- 241000589220 Acetobacter Species 0.000 description 1
- 108010013043 Acetylesterase Proteins 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 108010052875 Adenine deaminase Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010031025 Alanine Dehydrogenase Proteins 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 1
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
- 108091023020 Aldehyde Oxidase Proteins 0.000 description 1
- 102100036826 Aldehyde oxidase Human genes 0.000 description 1
- 108700023418 Amidases Proteins 0.000 description 1
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 description 1
- 102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 108010051152 Carboxylesterase Proteins 0.000 description 1
- 102000013392 Carboxylesterase Human genes 0.000 description 1
- 108010066477 Carnitine O-acetyltransferase Proteins 0.000 description 1
- 102100036357 Carnitine O-acetyltransferase Human genes 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 102000006378 Catechol O-methyltransferase Human genes 0.000 description 1
- 108020002739 Catechol O-methyltransferase Proteins 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 229910052684 Cerium Inorganic materials 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108010003989 D-amino-acid oxidase Proteins 0.000 description 1
- 102000004674 D-amino-acid oxidase Human genes 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 108090000698 Formate Dehydrogenases Proteins 0.000 description 1
- 108090000156 Fructokinases Proteins 0.000 description 1
- 102000003793 Fructokinases Human genes 0.000 description 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 102100022624 Glucoamylase Human genes 0.000 description 1
- 108010021582 Glucokinase Proteins 0.000 description 1
- 102000030595 Glucokinase Human genes 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 102000005731 Glucose-6-phosphate isomerase Human genes 0.000 description 1
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 108010020056 Hydrogenase Proteins 0.000 description 1
- 108010008292 L-Amino Acid Oxidase Proteins 0.000 description 1
- 102000007070 L-amino-acid oxidase Human genes 0.000 description 1
- 229930195714 L-glutamate Natural products 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 108010073450 Lactate 2-monooxygenase Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 102100036617 Monoacylglycerol lipase ABHD2 Human genes 0.000 description 1
- VEQPNABPJHWNSG-UHFFFAOYSA-N Nickel(2+) Chemical compound [Ni+2] VEQPNABPJHWNSG-UHFFFAOYSA-N 0.000 description 1
- 108010068005 Oxalate decarboxylase Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000001105 Phosphofructokinases Human genes 0.000 description 1
- 108010069341 Phosphofructokinases Proteins 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N Pyridoxal phosphate Natural products CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 108010011939 Pyruvate Decarboxylase Proteins 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 108010042687 Pyruvate Oxidase Proteins 0.000 description 1
- 241000235527 Rhizopus Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 102100039081 Steroid Delta-isomerase Human genes 0.000 description 1
- 108010055297 Sterol Esterase Proteins 0.000 description 1
- 102000000019 Sterol Esterase Human genes 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108010075344 Tryptophan synthase Proteins 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 102000005840 alpha-Galactosidase Human genes 0.000 description 1
- 108010030291 alpha-Galactosidase Proteins 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 108010027597 alpha-chymotrypsin Proteins 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 102000005922 amidase Human genes 0.000 description 1
- 108010003977 aminoacylase I Proteins 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 108010009043 arylesterase Proteins 0.000 description 1
- 102000028848 arylesterase Human genes 0.000 description 1
- NGPGDYLVALNKEG-UHFFFAOYSA-N azanium;azane;2,3,4-trihydroxy-4-oxobutanoate Chemical compound [NH4+].[NH4+].[O-]C(=O)C(O)C(O)C([O-])=O NGPGDYLVALNKEG-UHFFFAOYSA-N 0.000 description 1
- 229910001422 barium ion Inorganic materials 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 108010047754 beta-Glucosidase Proteins 0.000 description 1
- 102000006995 beta-Glucosidase Human genes 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 108010023646 cortisone alpha-reductase Proteins 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 108010090785 inulinase Proteins 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 108010086351 lysine racemase Proteins 0.000 description 1
- 239000004337 magnesium citrate Substances 0.000 description 1
- 229960005336 magnesium citrate Drugs 0.000 description 1
- 235000002538 magnesium citrate Nutrition 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940095060 magnesium tartrate Drugs 0.000 description 1
- MUZDLCBWNVUYIR-ZVGUSBNCSA-L magnesium;(2r,3r)-2,3-dihydroxybutanedioate Chemical compound [Mg+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O MUZDLCBWNVUYIR-ZVGUSBNCSA-L 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910001453 nickel ion Inorganic materials 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 125000000914 phenoxymethylpenicillanyl group Chemical group CC1(S[C@H]2N([C@H]1C(=O)*)C([C@H]2NC(COC2=CC=CC=C2)=O)=O)C 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 108010064607 phosphoglucokinase Proteins 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 108010016297 plasmin drug combination deoxyribonuclease Proteins 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- AVTYONGGKAJVTE-OLXYHTOASA-L potassium L-tartrate Chemical compound [K+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O AVTYONGGKAJVTE-OLXYHTOASA-L 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 239000001472 potassium tartrate Substances 0.000 description 1
- 229940111695 potassium tartrate Drugs 0.000 description 1
- 235000011005 potassium tartrates Nutrition 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 108010085346 steroid delta-isomerase Proteins 0.000 description 1
- 229910001427 strontium ion Inorganic materials 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000004065 wastewater treatment Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Landscapes
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Abstract
Description
【発明の詳細な説明】
A、 の1
本発明はバイオリアクターなどに用いられる酵素および
微生物等の生体触媒固定化成形物の製造方法に関する。DETAILED DESCRIPTION OF THE INVENTION A. Part 1 The present invention relates to a method for producing a molded article on which biocatalysts such as enzymes and microorganisms are immobilized for use in bioreactors and the like.
ている。ing.
生体触媒を固定化する方法の一つに、高分子素材を用い
て生体触媒をそのまま包み込む包括固定化法があり、こ
の方法によく用いられる高分子素材として、寒天、アル
ギン酸塩、カラギーナン、ポリアクリルアミド、ポリビ
ニルアルコール、光硬化性樹脂等がある。このうち、ポ
リビニルアルコール(以下PVAと略記することがある
)含水ゲルは、生体触媒を包括させることにより、優れ
た固定化担体として利用できることが知られている。One method for immobilizing biocatalysts is entrapping immobilization, in which the biocatalyst is wrapped in a polymeric material. Examples of polymeric materials commonly used in this method include agar, alginate, carrageenan, and polyacrylamide. , polyvinyl alcohol, photocurable resin, etc. Among these, it is known that polyvinyl alcohol (hereinafter sometimes abbreviated as PVA) hydrogel can be used as an excellent immobilization carrier by entrapping a biocatalyst.
一方、この包括固定化によって生体触媒を固定化して生
体反応を行なわせる反応槽には、固定層(充填層)、流
動層、撹拌槽等があるが、これらの反応槽で用いられる
固定化担体の形状としては、活性表面が広くとれる点、
流動性や充填効果が良い点、取り扱いの容易さから、球
体であることが望ましい。On the other hand, reaction vessels in which biocatalysts are immobilized by comprehensive immobilization to perform biological reactions include fixed beds (packed beds), fluidized beds, stirred vessels, etc., and the immobilization carriers used in these reaction vessels are The shape allows for a wide active surface;
A spherical shape is desirable because of its good fluidity, good filling effect, and ease of handling.
特に、工業上の実用面において、高強度で球状の固定化
担体が容易に、かつ安価に製造可能なことが重要である
。In particular, from an industrial practical standpoint, it is important that a spherical immobilization carrier with high strength can be produced easily and at low cost.
従来、生体触媒の固定化担体として広く用いられている
アルギン酸塩は、常温でアルギン酸ナトリウム水溶液を
、Ca″”、 Al″゛のようなカチオンを含む水溶液
に滴下すると、容易に球体のゲルを形成する安価で使い
やすいゲルである。しかしながら、アルギン酸塩のゲル
はリン酸塩でゲルが破壊したり、排水処理等の利用にお
いてはゲルそのものが浸食、溶解することもある。また
、機械的強度も必ずしも充分といえず、反応槽での長期
間の使用において損壊することが多い。Conventionally, alginate, which has been widely used as an immobilized support for biocatalysts, easily forms a spherical gel when a sodium alginate aqueous solution is dropped into an aqueous solution containing cations such as Ca'''' and Al'' at room temperature. It is an inexpensive and easy-to-use gel.However, alginate gels can be destroyed by phosphates, and the gel itself can be eroded and dissolved when used for wastewater treatment.Alginate gels also have poor mechanical strength. It is not always sufficient and is often damaged during long-term use in a reaction tank.
また、光硬化性樹脂やアクリルアミドから形成されるゲ
ルも、常温で球状化して使用できるが、これらはPVA
ゲルに比べ原料価格が非常に高価なため、生体触媒の包
括固定化担体として実用面、(ヨ、H,JO(ilIi
値(7)高イ生体反応zOIJ11:IiA。Gels formed from photocurable resins and acrylamide can also be used after being made into spheres at room temperature;
Since the raw material price is very expensive compared to gel, it is difficult to use (Y, H, JO (ilIi
Value (7) High biological reaction zOIJ11:IiA.
従来、PVAゲルを球体に成形する方法としては、PV
A水溶液を凍結−解凍する方法、PVA水溶液を宵機溶
媒や飽和ホウ酸水溶液中に滴下しゲル化する方法、また
、PVA水溶液を硫酸塩水溶液中に滴下し凝固させる方
法が知られている。Conventionally, as a method for molding PVA gel into a sphere, PV
A method of freezing and thawing an aqueous solution, a method of dropping a PVA aqueous solution into a solvent or a saturated boric acid aqueous solution to form a gel, and a method of dropping a PVA aqueous solution into a sulfate aqueous solution and solidifying it are known.
C1が 決しようとする課題
球状のPVAゲルを製造するため、凍結−解凍を行なう
方法は、冷凍庫等の凍結設備が必要となり、凍結のため
に大量のエネルギーと時間を要する。多量の球状のPV
Aゲルを連続的に製造するには、設備的にも、エネルギ
ー的にも好ましい方法とは言えない。Problems to be Solved by C1 In order to produce spherical PVA gel, the freeze-thaw method requires freezing equipment such as a freezer, and requires a large amount of energy and time for freezing. Large amount of spherical PV
In order to continuously produce A-gel, this method cannot be said to be preferable in terms of equipment and energy.
さらに、メタノール等の有機溶剤、あるいはホウ酸等の
酸・塩基性溶媒中でPVA水溶液を球体成形する方法も
、溶媒による生体触媒への悪影響が予想され、生体触媒
固定化成形物の製造方法としては望ましくない方法であ
り、適用範囲に制限を受ける。Furthermore, the method of molding a PVA aqueous solution into spheres in an organic solvent such as methanol or an acidic/basic solvent such as boric acid is also expected to have an adverse effect on the biocatalyst due to the solvent. is an undesirable method and limits its scope of application.
また、硫酸塩水溶液等のPVAの離液作用のある化合物
を含有する液体に直接PVA水溶液を滴下する方法では
、凝固速度が遅いために完全な球状ゲルが得られないと
いう欠点があった。Furthermore, a method in which a PVA aqueous solution is directly dropped into a liquid containing a compound having a synergic effect on PVA, such as a sulfate aqueous solution, has the disadvantage that a perfectly spherical gel cannot be obtained due to the slow coagulation rate.
また、重合度1000〜2000程度のPVAを用いた
従来のPVAゲルは、一部のPVAが水中へ溶出すると
いう問題があり、−層の耐久性の向上が望まれていた。Furthermore, conventional PVA gels using PVA with a degree of polymerization of about 1000 to 2000 have a problem in that some PVA dissolves into water, and it has been desired to improve the durability of the -layer.
本発明は、以上の諸問題点を解決するものであり、装置
的にもエネルギー的にも不利な凍結操作を行なわず、か
つ生体触媒に悪影響を与えるような溶媒を使用しないで
、PVAゲルが本来有する高含水で多孔質である特徴を
生かし、高強度で耐水性の高い球状の生体触媒固定化成
形物の製造が可能となった。The present invention solves the above-mentioned problems, and allows PVA gel to be produced without using a freezing operation that is disadvantageous in terms of equipment or energy, and without using a solvent that has an adverse effect on the biocatalyst. Taking advantage of its inherent characteristics of high water content and porousness, it has become possible to produce a spherical biocatalyst-immobilized molded product with high strength and high water resistance.
D、 を ° ための
本発明により得られた球状のPVAゲルは、生体触媒と
の親和性に富み、各種の反応形式にも適用できる強度と
耐久性を有し、また、耐水性、耐薬品性に優れており、
生体触媒の包括固定化担体として望ましい特徴を備えて
いる。D. The spherical PVA gel obtained according to the present invention has a high affinity with biocatalysts, has strength and durability that can be applied to various reaction formats, and is also water resistant and chemical resistant. Excellent in sex,
It has desirable characteristics as an entrapping immobilization support for biocatalysts.
(A)生体触媒、(B)重合度2800以上+7)PV
A、(C)少なくとも1種のカチオンとの接触によりゲ
ル化する能力のある水溶性高分子多糖類を含有する混合
水溶液を、カチオン含有水溶液と接触させることにより
、容易に真球に近い球体が形成され、直ちに表面が固化
し、球状成形物が相互に融着することなく、また、その
後の成形物の取扱いに対して、充分な強度を有するPV
Ali合水溶液の球状成形物が得られる。(A) Biocatalyst, (B) Degree of polymerization 2800 or more + 7) PV
A, (C) By bringing a mixed aqueous solution containing a water-soluble polymeric polysaccharide capable of gelling upon contact with at least one type of cation with an aqueous cation-containing solution, a sphere close to a true sphere can be easily formed. PV that is formed, has a solid surface immediately, does not allow the spherical molded products to fuse together, and has sufficient strength for subsequent handling of the molded product.
A spherical molded product of the Ali aqueous solution is obtained.
得られたPVA混合水溶液の球状成形物をカチオン含有
水溶液と分離して水洗後、PVAの離液作用のある化合
物の水溶液に浸漬させる。これにより、PVAがゲル化
し、球状のPVAゲルが得られる。The obtained spherical molded product of the PVA mixed aqueous solution is separated from the cation-containing aqueous solution, washed with water, and then immersed in an aqueous solution of a PVA compound having a synergic action. As a result, PVA gels and a spherical PVA gel is obtained.
このように、成形・ゲル化という2段階の工程をとるこ
とにより、真球状のPVAゲルが得られることを見出し
た。It was thus discovered that a truly spherical PVA gel could be obtained by performing the two-step process of molding and gelation.
以上のようにして得られたPVAゲルは、PVAゲル本
来の特徴を有するとともに球状で高強度であり、その製
造方法は、従来の球状PVAゲル製造方法に比べ容易か
つ安価である。The PVA gel obtained as described above has the characteristics inherent to PVA gel, is spherical and has high strength, and the method for producing it is easier and cheaper than the conventional method for producing spherical PVA gel.
以下、本発明の球状の生体触媒固定化成形物の製造方法
につき、より詳細に説明する。Hereinafter, the method for manufacturing the spherical biocatalyst-immobilized molded article of the present invention will be explained in more detail.
ここで本発明において使用される(A)生体触媒として
は、特に制約はなく、いかなる微生物および酵素も本発
明により固定され得る。微生物の代表例を挙げるならば
、アスペルギルス(^sper−gillus)属、リ
ゾプス(Rh1zopus )属等のかび類;シュード
モナス(Pseudotaonas)属、アセトバクタ
ー(Acetobactor)属、ストレプトマイセス
(Strep−tomyces )属、ニジエリシア(
Esch−erichia)属等の細菌;サツカロマイ
セス(Sac−charomyces )属、キャンデ
イダ(Candida)属等の酵母を挙げることができ
る。また、酵素の代表例を挙げるならば、ラクテートヒ
ドロゲナーゼ(1,1,2,3) 、ラクテートオキシ
ダーゼ(1,1!。There are no particular restrictions on the biocatalyst (A) used in the present invention, and any microorganisms and enzymes can be immobilized according to the present invention. Typical examples of microorganisms include molds such as the genus Aspergillus and the genus Rhizopus; the genus Pseudomonas, the genus Acetobacter, and the genus Streptomyces. , Nijierisia (
Bacteria such as the genus Esch-erichia; yeasts such as the genus Saccharomyces and the genus Candida. Typical examples of enzymes include lactate hydrogenase (1, 1, 2, 3) and lactate oxidase (1, 1!).
2)、グルコースオキシダーゼ(1,1J、4) 、ホ
ルメートデヒドロゲナーゼ(1,2,1,2) 、アル
デヒドデヒドロゲナーゼ(1,2,1J) 、アルデヒ
ドオキシダーゼ(1,2,3,1) 、キサンチンオキ
シダーゼ(1,2,3,2) 、ピルビン酸オキシダー
ゼ(1,24゜3)、ピルビン酸リダクターゼ(L、2
.4.1) 、コルチゾン−α−リダクターゼ(1,3
,1,4) 、アシルCo^−デヒドロゲナーゼ(13
,99,3) 、3−ケトステロイドΔ1−デヒドロゲ
ナーゼ(lJ、99.4)、3−ケトステロイドΔ4−
デヒドロゲナーゼ(1,3゜99.5) 、L−アラニ
ンデヒドロゲナーゼ(1,4,1゜1)、L−グルタミ
ン酸デヒドロゲナーゼ(1,4,1゜3)、L−アミノ
酸オキシダーゼ(1,4,3,2) 、D−アミノ酸オ
キシダーゼ(1,4,3,3) 、ピリドキサルリン酸
オキシダーゼ(1,4,3,5) 、カタラーゼ(1,
11,1,6) 、カテコールメチルトランスフェラー
ゼ(2,1,1,6) 、カルニチンアセチルトランス
フェラーゼ(2J、1.7) 、アセチルCO^アセチ
ルトランスフェラーゼ(2,3,1,9) 、アスベル
テートアミノトランスフエラーゼ(2,6,1,1)
、アラニンアミノトランスフェラーゼ(2,6゜1.2
) 、ピリドキサミンピルベートトランスフェラーゼ(
2゜6.1) 、ヘキソキナーゼ(2,7,11) 、
グルコキナーゼ(2,7,1,2) 、フルクトキナー
ゼ(2,7,1,4)、ホスホグルコキナーゼ(2,7
,1,1(1) 、ホスホフルクトキナーゼ(2,7,
1,11) 、ピルベートキナーゼ(2,7,1,40
) 、カルボキシエステラーゼ(3,1,1゜1)、ア
リールエステラーゼ(3,1,1,2) 、リパーゼ(
3,1,1,3) 、ホスホリパーゼA (3,1,1
,4)、アセチルエステラーゼ(3,1,1,6) 、
コレステロールエステラーゼ(3,1,1,13) 、
グルコアミラーゼ(3,2,1,3) 、セルラーゼ(
3,2,1,4) 、イヌラーゼ(3,2,1,7)
、α−グルコシダーゼ(3,2,1゜20)、β−グル
コシダーゼ(3,2,1,21) 、α−ガラクトシダ
ーゼ(3,2,1,22) 、β−ガラクトシダーゼ(
3,2,1,23) 、インベルターゼ(3,2,1,
26)、ペプシン(3,4,4,1)、トリプシン(3
,4,4,4)、キモトリプシンA (3,4,4,5
) 、カラプシンA(3゜4)、パパイン(3,4,4
,40)、トロンビン(3,4,4゜13)、アミダー
ゼ(3,5,1,4) 、ウレアーゼ(3,5゜1.5
) 、ペニシリンアシダーゼ(3,5,1,11) 、
アミノアシラーゼ(3,5,1,14) 、アデニンデ
アミナーゼ(3,5,4,2) 、A 、T 、P 、
アーゼ(3,6,1,3)、ピルベートデカルボキシラ
ーゼ(4,1,1,1) 、オキザレートデカルボキシ
ラーゼC4,1,1,2)、トリプトファンデカルボキ
シラーゼ(4,1,1,27)、アルドラーゼ(4,1
,2,13) 、マ゛レトトシュダーゼ(4,1,3,
2)、トリプトファンシンターゼ(4,2,1゜20)
、アスペルギルス(4,3,1,l) 、リジンラセマ
ーゼ(5,1,1,5) 、グルコ−ルー6−リン酸イ
ソメラーゼ(5,3,1,9) 、ステロイドΔ−イソ
メラーゼ(5,3,:(,1) 、vクシニルCoAシ
ンセターゼ(、6,2,1,5)、[(註)カッコ内の
数字は酵素番号を表わす]などが挙げられる。2), glucose oxidase (1,1J,4), formate dehydrogenase (1,2,1,2), aldehyde dehydrogenase (1,2,1J), aldehyde oxidase (1,2,3,1), xanthine oxidase (1,2,3,2), pyruvate oxidase (1,24°3), pyruvate reductase (L,2
.. 4.1), cortisone-α-reductase (1,3
, 1, 4), acyl Co^-dehydrogenase (13
,99,3), 3-ketosteroid Δ1-dehydrogenase (lJ, 99.4), 3-ketosteroid Δ4-
Dehydrogenase (1,3°99.5), L-alanine dehydrogenase (1,4,1°1), L-glutamate dehydrogenase (1,4,1°3), L-amino acid oxidase (1,4,3, 2), D-amino acid oxidase (1,4,3,3), pyridoxal phosphate oxidase (1,4,3,5), catalase (1,
11,1,6), catechol methyltransferase (2,1,1,6), carnitine acetyltransferase (2J, 1.7), acetyl CO^acetyltransferase (2,3,1,9), asbertate aminotransferase Elase (2,6,1,1)
, alanine aminotransferase (2,6°1.2
), pyridoxamine pyruvate transferase (
2゜6.1), hexokinase (2,7,11),
glucokinase (2,7,1,2), fructokinase (2,7,1,4), phosphoglucokinase (2,7
, 1, 1 (1), phosphofructokinase (2, 7,
1,11), pyruvate kinase (2,7,1,40
), carboxylesterase (3,1,1゜1), arylesterase (3,1,1,2), lipase (
3,1,1,3), phospholipase A (3,1,1
, 4), acetyl esterase (3, 1, 1, 6),
Cholesterol esterase (3,1,1,13),
glucoamylase (3,2,1,3), cellulase (
3,2,1,4), inulase (3,2,1,7)
, α-glucosidase (3,2,1°20), β-glucosidase (3,2,1,21), α-galactosidase (3,2,1,22), β-galactosidase (
3,2,1,23), invertase (3,2,1,
26), pepsin (3,4,4,1), trypsin (3
, 4, 4, 4), Chymotrypsin A (3, 4, 4, 5)
), calapsin A (3°4), papain (3,4,4
, 40), thrombin (3,4,4゜13), amidase (3,5,1,4), urease (3,5゜1.5)
), penicillin acidase (3,5,1,11),
Aminoacylase (3,5,1,14), adenine deaminase (3,5,4,2), A, T, P,
pyruvate decarboxylase (4,1,1,1), oxalate decarboxylase C4,1,1,2), tryptophan decarboxylase (4,1,1,27) ), aldolase (4,1
, 2, 13), maletotosudase (4, 1, 3,
2), tryptophan synthase (4,2,1°20)
, Aspergillus (4,3,1,l), lysine racemase (5,1,1,5), glucose-6-phosphate isomerase (5,3,1,9), steroid Δ-isomerase (5,3 , :(,1), v-cucinyl-CoA synthetase (,6,2,1,5), [(Note) The number in parentheses represents the enzyme number], and the like.
本発明に使用する(B)P V Aは平均重合度が28
00以上、好ましくは30H以上で、ケン化度は98.
5モル%以上、好ましくはケン化度99.85モル%以
上の完全ケン化PVAがゲルの形成上、望ましい。また
本発明のPVAとしては、本発明の目的を阻害しない範
囲において、公知の種々の変性PVAを用いることがで
きる。(B) PVA used in the present invention has an average degree of polymerization of 28
00 or more, preferably 30H or more, and the degree of saponification is 98.
Completely saponified PVA with a saponification degree of 5 mol % or more, preferably 99.85 mol % or more is desirable from the viewpoint of gel formation. Furthermore, as the PVA of the present invention, various known modified PVAs can be used within the range that does not impede the purpose of the present invention.
PVA水溶液の濃度が高いほど、より強固なゲルが生成
するが、必要なゲル強度が得られれば、p VA濃度が
低い方が原料コスト面から有利である。PVA以外の添
加成分の種類や濃度、PVA混合水溶液の液温および液
滴形成法によって、適切な濃度を選定する必要はあるが
、常温でPVA混合水溶液を滴下する場合は、PVA濃
度0.3〜10vt%が球状化が容易であり、実用上充
分なゲル強度が得られる。The higher the concentration of the PVA aqueous solution, the stronger the gel produced; however, as long as the required gel strength is obtained, a lower PVA concentration is advantageous in terms of raw material cost. Although it is necessary to select an appropriate concentration depending on the type and concentration of additive components other than PVA, the temperature of the PVA mixed aqueous solution, and the droplet formation method, when dropping the PVA mixed aqueous solution at room temperature, the PVA concentration is 0.3. When the content is 10 vt%, spheroidization is easy and a practically sufficient gel strength can be obtained.
本発明における、(C)少なくとも1種のカチオンとの
接触によりゲル化する能力のある水溶性高分子多糖類と
しては、具体的には、水溶性アルギン酸塩、カラギーナ
ン、マンナン、キトサン等が挙げられるが、とりわけア
ルギン酸ナトリウムが好ましい。In the present invention, (C) water-soluble polymeric polysaccharides capable of gelling upon contact with at least one cation include, specifically, water-soluble alginate, carrageenan, mannan, chitosan, etc. However, sodium alginate is particularly preferred.
PVA水溶液に添加する(C)少なくとも1種のカチオ
ンとの接触によりゲル化する能力のある水溶性高分子多
糖類、好適にはアルギン酸ナトリウムの濃度は、水に対
して0.2〜4vt%、好ましくは0.5〜2wt%が
良い。0.2vt%未満では、PVA混合水溶液の球状
化形成能が乏しく、また、4vt%より大の場合は、固
い球状成形物が得られるが、溶液粘度の上昇をもたらす
上、原料コスト上昇の要因となり好ましくない。The concentration of (C) a water-soluble polymer polysaccharide capable of gelling upon contact with at least one cation, preferably sodium alginate, added to the PVA aqueous solution is 0.2 to 4 vt% based on water; Preferably it is 0.5 to 2 wt%. If it is less than 0.2vt%, the spheroidization ability of the PVA mixed aqueous solution is poor, and if it is more than 4vt%, a hard spherical molded product can be obtained, but the solution viscosity increases and the cost of raw materials increases. This is undesirable.
また本発明における、カチオン含有化合物としては、具
体的には、カルシウムイオン、マグネシウムイオン、ス
トロンチウムイオン、バリウムイオン、アルミニウムイ
オン、カリウムイオン、セリウムイオン、ニッケルイオ
ン等の金属カチオン;アンモニウムイオンなどのカチオ
ンのうちの少なくとも1種を含有する化合物が挙げられ
るが、なかでも2価以上のカチオン含有化合物が好まし
く、とりわけCaC1*が望ましい。In the present invention, cation-containing compounds include, specifically, metal cations such as calcium ions, magnesium ions, strontium ions, barium ions, aluminum ions, potassium ions, cerium ions, and nickel ions; cations such as ammonium ions; Examples include compounds containing at least one of them, and among them, compounds containing divalent or higher cations are preferred, and CaC1* is particularly desirable.
また本発明における、ポリビニルアルコールの離液作用
のある化合物水溶液としては、硫酸ナトリウム、硫酸ア
ンモニウム、硫酸カリウム、硫酸マグネシウム、硫酸ア
ルミニウム、クエン酸ナトリウム、クエン酸アンモニウ
ム、クエン酸カリウム、クエン酸マグネシウム、クエン
酸アルミニウム、酒石酸ナトリウム、酒石酸アンモニウ
ム、酒石酸カリウム、酒石酸マグネシウム、酒石酸アル
ミニウム等の化合物のうちのうち少なくとも1種を含有
する液体が挙げられるが、コスト面からとりわけ硫酸塩
水溶液が好ましい。In the present invention, examples of the aqueous solution of a polyvinyl alcohol compound having a synergic effect include sodium sulfate, ammonium sulfate, potassium sulfate, magnesium sulfate, aluminum sulfate, sodium citrate, ammonium citrate, potassium citrate, magnesium citrate, and citric acid. Examples include liquids containing at least one of compounds such as aluminum, sodium tartrate, ammonium tartrate, potassium tartrate, magnesium tartrate, and aluminum tartrate, but sulfate aqueous solutions are particularly preferred from the viewpoint of cost.
次に、前述の各成分を用いた球状成形物の調製方法につ
いて説明する。Next, a method for preparing a spherical molded article using each of the above-mentioned components will be explained.
(B)重合度2800以上のPVAと(C)少なくとも
1種のカチオンとの接触によりゲル化する能力のある水
溶性高分子多糖類の水溶液に目的とする生体触媒を混入
、撹拌してPVA混合水溶液を調製する。(B) PVA with a degree of polymerization of 2800 or higher and (C) A desired biocatalyst is mixed into an aqueous solution of a water-soluble polymeric polysaccharide capable of gelling upon contact with at least one type of cation, and the mixture is mixed with PVA by stirring. Prepare an aqueous solution.
また、このPVA混合水溶液には、PVAのゲル化を阻
害しない範囲で、微生物の培地、固定化担体の強度を上
げるための補強剤、生成ゲルの比重を調整する充填材等
を添加してもよい。In addition, a microorganism culture medium, a reinforcing agent to increase the strength of the immobilization carrier, a filler to adjust the specific gravity of the produced gel, etc. may be added to this PVA mixed aqueous solution within a range that does not inhibit the gelation of PVA. good.
以上のPVA混合水溶液を例えば、管状の口金から滴下
させるか、または噴霧口金から噴霧させることによって
液滴を形成させ、次いで該液滴をカチオン含有化合物、
好適にはCaCItを含有する水溶液と接触させる。P
VA混合水溶液の液滴は、C1CL水溶液に接触すると
表面張力によって球状となり、更に球体の最表面が薄膜
状に固化して、PVA混合水溶液の球状成形物となる。The above PVA mixed aqueous solution is, for example, dropped from a tubular cap or sprayed from a spray cap to form droplets, and then the droplets are mixed with a cation-containing compound,
Contact is preferably made with an aqueous solution containing CaCIt. P
When the droplets of the VA mixed aqueous solution come into contact with the C1CL aqueous solution, they become spherical due to surface tension, and the outermost surface of the sphere solidifies into a thin film, forming a spherical molded product of the PVA mixed aqueous solution.
球状成形物の直径は口金の直径、噴霧圧力、PVA混合
水溶液の粘度を調整することによって、直径1mm〜1
0■■に任意に変えられる。CaC1を水溶液は静置水
でもよいが、スターラー等で強制撹拌することによって
、PVA混合水溶液の成形物とCaC1g水溶液の反応
速度を促進し、球状成形物どうしの融着をほぼ完全に防
止できる。実用上、多量のPVAゲルを製造する場合、
球状成形物の直径を揃えるには、PVA混合水溶液を滴
下させるための押し出しにポンプ等を用いることができ
る。例えばフレキシブルなチューブを圧縮して送液する
ローラーポンプを用いると、口金からの吐出が一定量と
なり均一な球状成形物が得られやすい。The diameter of the spherical molded product can be adjusted from 1 mm to 1 mm by adjusting the diameter of the cap, the spray pressure, and the viscosity of the PVA mixed aqueous solution.
Can be arbitrarily changed to 0■■. The CaCl aqueous solution may be left in standing water, but by forcibly stirring it with a stirrer or the like, the reaction rate between the molded PVA mixed aqueous solution and the CaCl1g aqueous solution can be accelerated, and fusion of the spherical molded products can be almost completely prevented. In practice, when producing a large amount of PVA gel,
In order to make the diameter of the spherical molded product uniform, a pump or the like can be used for extrusion to drip the PVA mixed aqueous solution. For example, if a roller pump is used that compresses a flexible tube and delivers the liquid, a constant amount of liquid is discharged from the mouthpiece, making it easy to obtain a uniform spherical molded product.
CaC1を水溶液中で球状化したPVA水溶液成形物は
CaCl5水溶液と分離して水洗後、NatSO,水溶
液に浸漬させる。hatsOt水溶液の濃度はLOOg
/ Q以上でよいが、より強力なPVAゲルを得るには
、飽和溶液が望ましい。浸漬時間は、10分以上、好ま
しくは30分以上がよい。NatSO,水溶液に浸漬す
ることにより、PVAがゲル化し、球状のPVAゲルが
得られる。The PVA aqueous solution molded product obtained by spheroidizing CaCl in an aqueous solution is separated from the CaCl5 aqueous solution, washed with water, and then immersed in a NatSO aqueous solution. The concentration of hatsOt aqueous solution is LOOg
/Q or higher is sufficient, but a saturated solution is desirable to obtain a stronger PVA gel. The immersion time is preferably 10 minutes or more, preferably 30 minutes or more. By immersing it in NatSO, aqueous solution, PVA gels and a spherical PVA gel is obtained.
このようにして得られたPVAゲルは、各種の形式の反
応槽において、長期間にわたって変形、損壊しない強度
を有し、水や各種薬液に対しても侵されることなく、連
続運転が可能となり、生体触媒固定化成形物としての実
用性が発現する。The PVA gel thus obtained has a strength that will not deform or break over a long period of time in various types of reaction vessels, and can be operated continuously without being attacked by water or various chemical solutions. It has practical utility as a biocatalyst immobilized molded product.
E、L九1
以下、実施例により本発明を具体的に説明するが、本発
明はこれらの実施例により限定されるものではない。E, L91 Hereinafter, the present invention will be specifically explained with reference to Examples, but the present invention is not limited to these Examples.
実施例!
(株)クラレ製のポリビニルアルコール(PVA)(平
均重合度3300、ケン化度99.85モル%)を40
℃の温水で約1時間洗浄後、PVA濃度10vt%にな
るようにPVAに水を加え全量を400gにしてPH6
に調整した。これをオートクレーブで120℃、30分
処理し、PVAを溶解した後、室温まで放冷した。この
PVA水溶液に4%アルギン酸ナトリウム水溶液200
gを加えて混合し、さらに(株)クラレ岡山工場(岡山
県岡山市海岸通りi丁目2番1号)の排水処理槽より検
収し、濃縮操作を施して得られた活性汚泥菌(濃度M
L S S 80000a+g/12)を200g加
え、充分に撹拌した。Example! Polyvinyl alcohol (PVA) manufactured by Kuraray Co., Ltd. (average degree of polymerization 3300, degree of saponification 99.85 mol%)
After washing with warm water at ℃ for about 1 hour, add water to PVA so that the PVA concentration is 10vt%, make the total amount 400g, and adjust the pH to 6.
Adjusted to. This was treated in an autoclave at 120°C for 30 minutes to dissolve PVA, and then allowed to cool to room temperature. Add 200% of 4% sodium alginate aqueous solution to this PVA aqueous solution.
Activated sludge bacteria (concentration M
200g of LSS 80000a+g/12) was added and thoroughly stirred.
これらの混合液を先端に内径0.8mmの注射針を取り
付けた内径2m@φのビニル管1本を使用したローラー
ポンプでlsQ/分で送液し、スターラーで撹拌した0
、5so(!/12塩化カルシウム(CaCL)水溶液
に氷表面5c−の高さより滴下した。滴下した液滴はC
aC1t水溶液中で直ちに球状化して沈降した。これら
の球状化したPVA混合成形物を全量CaC1t水溶液
と分離し、蒸留水で軽く洗浄した後、スターラーで撹拌
した飽和Na、So、水溶液に60分浸漬することによ
って、不透明な褐色の柔軟性に富んだ球状のゲルが得ら
れた。このゲルは球状に成形化され、粘着性もない。粒
径は3〜3.5■φであった。These mixed solutions were pumped at a rate of lsQ/min using a roller pump using a vinyl tube with an inner diameter of 2 m@φ and a syringe needle with an inner diameter of 0.8 mm attached to the tip, and stirred with a stirrer.
, 5so(!/12) was dropped into an aqueous solution of calcium chloride (CaCL) from a height of 5c- on the ice surface.
It immediately became spheroidized and precipitated in the aClt aqueous solution. These spheroidized PVA mixture moldings were separated from the CaClt aqueous solution, washed lightly with distilled water, and then immersed in a saturated Na, So, aqueous solution stirred with a stirrer for 60 minutes, giving them an opaque brown color. A rich spherical gel was obtained. This gel is shaped into spheres and is not sticky. The particle size was 3 to 3.5 .phi.
このようにして得られたPVAゲルについて水中へのP
VAの溶出量を測定した。ゲル30gに対して水300
gを加え、30℃にて7日間撹拌した。このときのPV
Aの溶出量はゲルIkgあたり1.2gであった。さら
に、このゲルを取り出して軽く水洗後、液切りをし、あ
らたに水300gを加えて、30℃にて7日間撹拌し、
このときのPVAの溶出量はゲル1kgあたり0.0g
であり、PVAの溶出量は非常に少なかった。Regarding the PVA gel obtained in this way, P in water
The elution amount of VA was measured. 30g of gel to 300g of water
g was added thereto, and the mixture was stirred at 30°C for 7 days. PV at this time
The elution amount of A was 1.2 g per Ikg of gel. Furthermore, this gel was taken out, washed lightly with water, drained, added 300 g of water, and stirred at 30°C for 7 days.
The elution amount of PVA at this time is 0.0g per 1kg of gel.
The amount of PVA eluted was very small.
比較例1
(株)クラレ製のPVA (平均重合度1740、ケン
化度99.85モル%)を用い、それ以外は実施例1と
全く同じ方法でゲルを作成した。Comparative Example 1 A gel was prepared in the same manner as in Example 1 except for using PVA manufactured by Kuraray Co., Ltd. (average degree of polymerization 1740, degree of saponification 99.85 mol%).
得られたゲルは、粘着性のない不透明な褐色の柔軟性に
富んだ直径3〜3.5mg+の球状ゲルであった。The resulting gel was a non-tacky, opaque brown, flexible spherical gel with a diameter of 3-3.5 mg+.
このようにして得られたPVAゲルについて、実施例1
と同じ方法で水中へのPVAの溶出量を測定した。最初
の7日間、次の7日間の溶出量はゲル1kgあたりそれ
ぞれ9.0g、 1.1gであり、溶出量が多かった。Regarding the PVA gel thus obtained, Example 1
The amount of PVA eluted into water was measured in the same manner as described above. The elution amounts for the first 7 days and the next 7 days were 9.0 g and 1.1 g per kg of gel, respectively, which were large amounts.
比較例2
(株)クラレ製のポリビニルアルコール(PVA)(平
均重合度1740、ケン化度99J5モル%)を40℃
の温水で約1時間洗浄後、PVA濃度10wt%になる
ようにPVAに水を加え全量を400gにしてPH6に
調整した。これをオートクレーブで120℃、30分処
理し、PVAを溶解した後、室温まで放冷した。これに
(株)クラレ岡山工場(岡山県岡山市海岸通り1丁目2
番1号)の排水処理槽より採取し、濃縮操作を施して得
られた活性汚泥菌(濃度M L S S 80000
eg/ Q)を200g加え、水を加えて全量を800
gとし、充分に撹拌した。これらの混合液を先端に内径
0.8鵬−の注射針を取り付けた内径2mmφのビニル
管1本を使用したローラーポンプで1m12/分で送液
し、スターラーで撹拌した濃度40g/Qのホウ酸水溶
液に氷表面5cmの高さより滴下し、24時間浸漬する
ことにより、PVAのホウ酸による佳境反応を行なわせ
、球状のゲルを得た。Comparative Example 2 Polyvinyl alcohol (PVA) manufactured by Kuraray Co., Ltd. (average degree of polymerization 1740, degree of saponification 99J5 mol%) was heated at 40°C.
After washing with warm water for about 1 hour, water was added to the PVA so that the PVA concentration was 10 wt%, the total amount was 400 g, and the pH was adjusted to 6. This was treated in an autoclave at 120°C for 30 minutes to dissolve PVA, and then allowed to cool to room temperature. In addition, Kuraray Okayama Factory (1-2 Kaigandori, Okayama City, Okayama Prefecture)
Activated sludge bacteria (concentration M L S S 80,000
Add 200g of eg/Q) and add water to bring the total amount to 800g.
g and stirred thoroughly. These mixed solutions were pumped at a rate of 1 m12/min using a roller pump using a vinyl pipe with an inner diameter of 2 mm and a syringe needle with an inner diameter of 0.8 mm attached to the tip, and the mixture was stirred with a stirrer to give a solution of 40 g/Q in concentration. By dropping the mixture into an acid aqueous solution from a height of 5 cm above the ice surface and immersing it for 24 hours, a favorable reaction of PVA with boric acid occurred, and a spherical gel was obtained.
このようにして得られたPVAゲルについて、実施例1
と同じ方法で水中へのPVAの溶出量を測定した。最初
の7日間、次の7日間の溶出量はゲル1kgあたりそれ
ぞれ19.5g、 9.8gであり、溶出量が非常に多
かった。Regarding the PVA gel thus obtained, Example 1
The amount of PVA eluted into water was measured in the same manner as described above. The elution amounts for the first 7 days and the next 7 days were 19.5 g and 9.8 g per kg of gel, respectively, which were extremely large amounts.
F、[1OxL
上記の実施例で明らかなとおり、本発明による重合度の
高いPVAからなる生体触媒固定化成形物は強度が高く
、十分な耐水性があり、バイオリアクター等への利用が
可能であり、工業的な価値が極めて高い。F, [1OxL As is clear from the above examples, the biocatalyst-immobilized molded product made of PVA with a high degree of polymerization according to the present invention has high strength and sufficient water resistance, and can be used in bioreactors, etc. It has extremely high industrial value.
Claims (4)
び、 (C)少なくとも1種のカチオンとの接触 によりゲル化する能力のある水溶性 高分子多糖類 を含有する混合水溶液の液滴をカチオン含有化合物を含
有する水溶液と接触させることにより、該混合水溶液を
球状に成形させた後、これをポリビニルアルコールの離
液作用のある化合物を含有する液体と接触させることに
より、ポリビニルアルコールをゲル化して得られること
を特徴とする球状の生体触媒固定化成形物の製造方法。(1) A mixture containing (A) a biocatalyst, (B) polyvinyl alcohol with a degree of polymerization of 2800 or more, and (C) a water-soluble polymeric polysaccharide capable of gelling upon contact with at least one cation. By bringing droplets of the aqueous solution into contact with an aqueous solution containing a cation-containing compound, the mixed aqueous solution is formed into a spherical shape, and then by contacting this with a liquid containing a compound having a synergic effect of polyvinyl alcohol, A method for producing a spherical biocatalyst-immobilized molded article, which is obtained by gelling polyvinyl alcohol.
ゲル化する能力のある水溶性高分子多糖類がアルギン酸
ナトリウムである請求項1記載の球状の生体触媒固定化
成形物の製造方法。(2) The method for producing a spherical biocatalyst-immobilized molded article according to claim 1, wherein (C) the water-soluble polymeric polysaccharide capable of gelling upon contact with at least one cation is sodium alginate.
項1または2記載の球状の生体触媒固定化成形物の製造
方法。(3) The method for producing a spherical biocatalyst-immobilized molded article according to claim 1 or 2, wherein the cation-containing compound is calcium chloride.
硫酸塩である請求項1〜3のいずれか1つの項に記載の
球状の生体触媒固定化成形物の製造方法。(4) The method for producing a spherical biocatalyst-immobilized molded article according to any one of claims 1 to 3, wherein the compound having a synergic effect on polyvinyl alcohol is a sulfate.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP33381189A JPH03195489A (en) | 1989-12-22 | 1989-12-22 | Production of spherical formed product of immobilized biocatalyst |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP33381189A JPH03195489A (en) | 1989-12-22 | 1989-12-22 | Production of spherical formed product of immobilized biocatalyst |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH03195489A true JPH03195489A (en) | 1991-08-27 |
Family
ID=18270216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP33381189A Pending JPH03195489A (en) | 1989-12-22 | 1989-12-22 | Production of spherical formed product of immobilized biocatalyst |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH03195489A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995002047A1 (en) * | 1993-07-06 | 1995-01-19 | Institut Oenologique De Champagne | Process for obtaining microorganism-enclosing biocatalysts, and biocatalysts thus obtained |
US5482932A (en) * | 1992-09-04 | 1996-01-09 | Courtaulds Fibres (Holdings) Limited | Alginate gels to the form of fibrous pastes useful as wound dressings |
WO1998004616A1 (en) * | 1996-07-31 | 1998-02-05 | Kanebo Limited | Porous spherical polyvinyl acetal particles, process for producing the same, and microbial carriers |
-
1989
- 1989-12-22 JP JP33381189A patent/JPH03195489A/en active Pending
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5482932A (en) * | 1992-09-04 | 1996-01-09 | Courtaulds Fibres (Holdings) Limited | Alginate gels to the form of fibrous pastes useful as wound dressings |
WO1995002047A1 (en) * | 1993-07-06 | 1995-01-19 | Institut Oenologique De Champagne | Process for obtaining microorganism-enclosing biocatalysts, and biocatalysts thus obtained |
FR2708281A1 (en) * | 1993-07-06 | 1995-02-03 | Champagne Inst Oenologique | Process for obtaining biocatalysts containing microorganisms and biocatalysts obtained. |
WO1998004616A1 (en) * | 1996-07-31 | 1998-02-05 | Kanebo Limited | Porous spherical polyvinyl acetal particles, process for producing the same, and microbial carriers |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0303122B1 (en) | Process for manufacturing spherical hydrated gel containing microorganism immobilized therein | |
KR920009499B1 (en) | Process for preparation of porous matters containing an enzyme immobilized by means of pva-gel | |
JP3908327B2 (en) | Polyvinyl alcohol-based hydrogel production method and enzyme / microbe-immobilized molded product production method | |
JPH03195489A (en) | Production of spherical formed product of immobilized biocatalyst | |
JP3287686B2 (en) | Polymeric granular hydrogel and method for producing the same | |
JP3466236B2 (en) | Polyvinyl acetal gel molding | |
JP2004075762A (en) | Method for producing polyvinyl alcohol-based hydrogel | |
JP2622170B2 (en) | Spherical polyvinyl alcohol-based hydrogel and method for producing the same | |
US5093253A (en) | Method for microbial immobilization by entrapment in gellan gum | |
JPS5974984A (en) | Preparation of immobilized enzyme or microorganism | |
JP2777211B2 (en) | Method for producing spherical biocatalyst-immobilized molded article | |
JPH08116974A (en) | Formed hydrous gel containing immobilized microorganism | |
JP3055963B2 (en) | Polymer gel for biocatalyst-immobilized moldings | |
JP3266607B2 (en) | Biocatalyst immobilized gel | |
JPS62138193A (en) | Production of immobilization granules of enzyme or microorganism | |
JPH02167077A (en) | Production of spherical enzyme immobilized molded article | |
JPH03236779A (en) | Biocatalyst-immobilized formed product and production thereof | |
JPH02211872A (en) | Production of formed spherical product immobilizing biocatalyst | |
JPH0657012A (en) | Production of polyvinyl-alcoholic gel formed articles | |
JP2710815B2 (en) | Gel substrate | |
JPH08239538A (en) | Pva hydrous gel and its production | |
JP2004075763A (en) | Polyvinyl alcohol hydrous gel and its manufacturing method | |
JPH02211875A (en) | Polyvinyl alcohol gelatinous fiber immobilizing biocatalyst and production thereof | |
JPH03236778A (en) | Biocatalyst-immobilized formed product and production thereof | |
JPS62186995A (en) | Microorganism immobilized carrier for waste water treatment and its production |